SLC5A2 and type 2 diabetes mellitus: Currently, only three studies have evaluated satisfaction with the use of SGLT2 inhibitors in patients with type 2 diabetes mellitus (Chirila et al., 2016; Nakajima et al., 2018) and those in type 1 diabetes mellitus (Ishibashi et al., 2021).